There are two primary types of drug therapy for
osteoporosis: antiresorptive agents and anabolic
agents. Antiresorptive drugs reduce bone loss, while
anabolic agents stimulate new bone formation. Antiresorptive
therapies include bisphosphonates, estrogen, selective
estrogen receptor modulators (SERMs), and calcitonin.
These agents act to lessen the risk of bone fracture
by decreasing bone turnover, reducing bone loss,
and stabilizing bone microarchitecture. Anabolic
therapy with teriparatide expands the treatment
approaches for osteoporosis in patients who continue
to experience fractures or bone loss on an adequate
program of general prevention and antiresorptive
therapy. Topics
covered in this program
- Antiresorptive therapies for the management
of osteoporosis
- Current recommendations on the use
of hormone therapy to prevent and treat osteoporosis
- Anabolic therapy for the treatment
of osteoporosis
- Combination therapy for the treatment
of osteoporosis
The American Medical Association is accredited by
the Accreditation
Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians.
The American Medical Association designates this
module for a maximum of 1.5 AMA PRA Category 1
Credits™. Physicians should only claim
credit commensurate with the extent of their participation
in the activity.
Nonphysicians may receive a certificate of participation
for completing this activity.
The development of this CME web module was supported
in part through an independent education grant from
the Alliance for Better Bone Health and produced in
accordance with the AMA Standards for Industry-Supported
Multimedia Continuing Medical Education and Other
Communications.
|
